Izofra nasal spray 8000 IU/ml. 15 ml. №1 vial

Description

Izofra nasal Storage:

active substance: framycetin;

1 ml of solution contains framycetin sulfate 12.5 mg (8000 IU);

Excipients: methylparaben (E 218), sodium chloride, sodium citrate, citric acid monohydrate, purified water.

Dosage form.

Nasal spray, solution.

Pharmacotherapeutic group.

Anti-edema and other drugs for topical use in the case of diseases of the nasal cavity. PBX code R01A X08.

Izofra nasal Clinical characteristics.

Indication.

As part of combination therapy for infectious and inflammatory diseases of the upper respiratory tract, including rhinitis, rhinopharyngitis, sinusitis in the absence of damage to the walls of the nasal sinuses; prevention and treatment of inflammatory processes after surgery.

Izofra nasal Contraindication.

Hypersensitivity (allergy) to any of the components of the drug, including framycetin and other antibiotics of the aminoglycoside group.

Children under 1 year.

Method of application and dosage.

Adults are prescribed 1 injection in each nasal passage 4-6 times a day.

Children over 1 year of age are prescribed one injection in each nasal passage 3 times a day. Injection is performed by pressing on the vial. When using, keep the vial upright and tilt your head slightly forward to inject the spray solution into the nasal passage, not a stream of liquid.

The duration of treatment is up to 10 days.

Adverse reactions.

In some cases, allergic reactions (urticaria, itching) may occur.

Overdose.

There were no cases of overdose.

Use during pregnancy or breastfeeding.

Efficacy and safety of the drug during pregnancy have not been studied enough.

Possible toxic effect on the cochleovestibular apparatus of the fetus. Systemic penetration through the mucous membrane is possible, so the drug should not be prescribed to this category of patients.

The use of the drug during breastfeeding is not recommended because aminoglycosides penetrate into breast milk.

Children.

It is used as prescribed by a doctor for the treatment of children over 1 year of age.

Features of application.

The drug should not be used for washing the paranasal sinuses. With prolonged use of the drug may develop resistant strains of microorganisms. If within 7 days of treatment the therapeutic effect is absent, the drug should be canceled.

Ability to influence the speed of reaction when driving a car or working with other mechanisms.

No cases of influence on the speed of reaction when driving vehicles or working with other mechanisms have been identified.

Interaction with other medicinal products and other forms of interaction.

Unknown.

Be sure to tell your doctor if you are taking any other topical medicines.

Pharmacological properties.

Pharmacodynamics.

Framycetin is a topical aminoglycoside antibiotic. The concentration of framycetin, which is achieved when applied topically, provides its bactericidal activity against gram-positive and gram-negative microorganisms, which cause the development of infectious processes in the upper respiratory tract.

Pharmacokinetics.

Pharmacokinetic studies have not been performed due to low systemic absorption.